Purpose: Perhexiline (Px) has previously been utilized primarily in the treatment of otherwise
refractory angina pectoris and/or systolic heart failure. In recent years, Px has also shown …

Perhexiline (Px) inhibits carnitine palmitoyltransferase 1 (CPT1), which controls uptake of
long chain fatty acids into mitochondria. However, occasional cases of hypoglycaemia have …

In heart failure with reduced ejection fraction, mechanical work produced by the left ventricle
to support the systemic circulation decreases over time despite relatively constant …

Introduction: The re-purposing of the anti-anginal drug perhexiline (PHX) has resulted in
symptomatic improvements in heart failure (HF) patients. The inhibition of carnitine …

Materials and Methods: Two hundred patients at steady-state on long-term perhexiline were
identified retrospectively. The ratio of maintenance dose to steady-state plasma …

Perhexiline was introduced about 30 years ago and rapidly gained a reputation for efficacy
in the management of angina pectoris. However, hepatic and neurological adverse effects …

Aims To examine whether the prophylactic antianginal agent perhexiline potentiates platelet
responsiveness to nitric oxide (NO) in patients with stable angina pectoris (SAP) and acute …

Approaches to the pharmacotherapy of angina pectoris have previously centred on the
concept that a transient imbalance between myocardial oxygen “demand” and supply within …

Background—Chronic heart failure (CHF) is a major cause of morbidity and mortality that
requires a novel approach to therapy. Perhexiline is an antianginal drug that augments …

Perhexiline, a “metabolic” anti-anginal agent currently under investigation in management of
congestive heart failure and acute coronary syndromes improves platelet nitric oxide …